Who are Avacta?
Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
At Avacta we have developed Affimer® technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.
Affimer® proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta took its first pre|CISIONTM drug candidate AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic in summer 2021.
“What really excites me, and drives the company, is the opportunity to change the way life scientists explore the complexity of the proteome and the myriad of interactions that define us as humans.”
Alastair Smith, CEO Avacta.